Previous 10 | Next 10 |
Federal prosecutors open a criminal investigation into whether opioid companies violated the federal Controlled Substances Act, according to WSJ sources . More news on: Teva Pharmaceutical Industries Limited, Mallinckrodt plc, Johnson & Johnson, Stocks on the move, Healthcare sto...
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that management will participate in a fireside chat at the Piper Jaffray 31st Annual Healthcare Conference in New York on Tuesday, December 3, 2019 at 10:00 a.m. Eastern Time. To access a live webcast of the presentation, visit Amn...
In July, I wrote an article on Amneal Pharmaceuticals, Inc. ( AMRX ) relating to the strong insider buying and how that could be seen as a positive catalyst. While insider buying is generally a good sign, there is no foolproof way to making money on the market. AMRX is a great example of thi...
The following slide deck was published by Amneal Pharmaceuticals, Inc. in conjunction with their 2019 Q3 earnings Read more ...
Alexion Pharmaceuticals (NASDAQ: ALXN ) initiated with Buy rating and $125 (15% upside) price target at SunTrust. More news on: Alexion Pharmaceuticals, Inc., Amgen Inc., Arcus Biosciences, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Image source: The Motley Fool. Amneal Pharmaceuticals, Inc. (NYSE: AMRX) Q3 2019 Earnings Call Nov 6, 2019 , 8:30 a.m. ET Operator Continue reading
Amneal Pharmaceuticals Inc. (AMRX) Q3 2019 Results Conference Call November 06, 2019 08:30 AM ET Company Participants Mark Donohue - Vice President of Investor Relations Chirag Patel - Co-Chief Executive Officer and President Chintu Patel - Co-Chief Executive Officer Todd Bra...
Amneal Pharmaceuticals ( AMRX -18.6% ) inks an agreement with privately held Kashiv BioSciences for exclusive U.S. rights to Phase 2-stage K127 (pyridostigmine) for the treatment of myasthenia gravis , a rare autoimmune disorder characterized by weakness in the skeletal muscles. More ...
Fluidigm (NASDAQ: FLDM ) -31% on Q3 results . More news on: Fluidigm Corporation, Plantronics, Inc., Amneal Pharmaceuticals, Inc., Stocks on the move, Read more ...
Amneal Pharmaceuticals (NYSE: AMRX ) Q3 results : More news on: Amneal Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Amneal Pharmaceuticals Inc. Class A Company Name:
AMRX Stock Symbol:
NASDAQ Market:
Amneal Pharmaceuticals Inc. Class A Website:
First presentation of preservative-free potassium phosphates in a single-dose IV infusion bag Third 505(b)(2) injectable added this year – will launch in third quarter Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) to...
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its second quarter 2024 financial results on Friday, August 9, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time. ...
FOCINVEZ (fosaprepitant) 150 mg/50 mL single dose vial is an anti-nausea agent for highly emetogenic and moderately emetogenic chemotherapy (HEC and MEC) Second injectable RTU product launched by Amneal in 2024 Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal”...